Results 1 to 10 of about 12,394 (158)
Endokrynologia Polska, 2021 INTRODUCTION: The effect of incretins including dipeptidyl peptidase 4 inhibitors (DPP4-Is) and glucagon-like peptide1 receptor agonists (GLP1-ras) in the treatment of type 2 diabetes increasing the risk of fracture remains controversial.
Qing-xin Kong +5 more
exaly +3 more sources
Bile acids and incretins as modulators of obesity-associated atherosclerosis. [PDF]
Front Cardiovasc MedObesity is one of the major global health concerns of the 21st century, associated with many comorbidities such as type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease, and early and aggressive atherosclerotic ...
Kirsch A +3 more
europepmc +2 more sources
Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection. [PDF]
Front Med (Lausanne)Endothelial dysfunction represents the critical pathophysiological mediator linking the modern epidemics of obesity, type 2 diabetes mellitus, and cardiovascular disease.
Battistoni A +5 more
europepmc +2 more sources
Physiological Reports, 2019 Bariatric surgery is now the most widely used intervention for the treatment of human obesity. A large body of literature has demonstrated its efficacy in sustained weight loss and improvement in its associated comorbidities.
Isabel Casimiro +2 more
exaly +2 more sources
Comparative effects of SGLT2 inhibitors and incretin-based therapies on dementia risk in type 2 diabetes: a systematic review and meta-analysis. [PDF]
Front Endocrinol (Lausanne)BackgroundAntidiabetic drugs lower blood glucose levels and may also have neuroprotective and vascular protection effects. In particular, sodium–glucose cotransporter 2 inhibitors (SGLT2is) and incretin mimetics have demonstrated dementia-reducing ...
Song K +6 more
europepmc +2 more sources
Pharmaceutics, 2023 Atherosclerosis is the leading cause of death worldwide, especially in patients with type 2 diabetes mellitus (T2D). GLP-1 receptor agonists and DPP-4 inhibitors were demonstrated to play a markedly protective role for the cardiovascular system beyond ...
ylenia la porta +2 more
exaly +3 more sources
Hyperglycaemia induced osteoporosis: Is there a hope with dipeptidyl peptidase-4 inhibitors?
Health Sciences Review, 2023 Diabetes mellitus and osteoporosis are chronic illnesses associated with adverse health outcomes. Studies have reported common linkages between energy and bone metabolism.
Faraha Ahmed +8 more
doaj +1 more source
Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020 [PDF]
Endocrinology and Metabolism, 2021 Over the last two decades, our understanding of diabetes and treatment strategies have evolved tremendously, from scientific, mechanistic, and human perspectives.
Eun-Jung Rhee +2 more
doaj +1 more source
Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes
Medicina, 2022 The current management of Type 2 Diabetes Mellitus (T2DM) includes incretin-based treatments able to enhance insulin secretion and peripheral insulin sensitivity as well as improve body mass, inflammation, plasma lipids, blood pressure, and ...
Angelo Maria Patti +10 more
doaj +1 more source
Scientific Reports, 2022 It has not been elucidated whether incretins affect insulin clearance in type 2 diabetes (T2D). We aimed exploring possible associations between insulin clearance and endogenously secreted or exogenously administered incretins in T2D patients. Twenty T2D
Andrea Tura +4 more
doaj +1 more source